IFRS Third-Quarter 2018 Results

IFRS Third-Quarter 2018 Results

In the third quarter of 2018 HAEMATO AG, Berlin (ISIN: DE0006190705), achieved IFRS consolidated sales of EUR 69.12 million (previous year: EUR 72.5 million). In the considered period of January till September 2018 the sales amounted to € 212.8 million (previous year:...
Half Year Report 2018

Half Year Report 2018

In the first half of 2018, the HAEMATO Group increased sales by 3.6 % year-on-year to a total of EUR 143.7 million. EBIT amounted to kEUR 6,484.6 (prior year period: kEUR 3,182.8). The consolidated profit as of 30.06.2018 amounts to kEUR 5,044.5 and is therefore also...
IFRS results Q1 2018

IFRS results Q1 2018

HAEMATO AG is a listed pharmaceutical company focusing on the growth markets of high-priced special pharmaceuticals from the indication areas oncology and HIV as well as in the areas of rheumatism, neurology and cardiovascular diseases. In addition, the company...
Annual Report 2017

Annual Report 2017

HAEMATO AG is a listed pharmaceutical company with a focus on the growth markets of special pharmaceuticals, primarily in the high-priced indication areas of oncology and HIV as well as rheumatism, neurology and cardiovascular diseases. HAEMATO AG had a successful...